Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs
Summary
Now the Watertown, MA-based company is considering tapping the public markets to add enough funds to move one of its pair of core drug candidates further along in the clinic and to start human tests of the other. Late last year Global Blood Therapeutics (NASDAQ: GBT) won FDA approval for its once-daily sickle cell disease drug. The UK’s CellCentric is also aiming to treat mCRPC with a CBP/p300 inhibitor of its own; Cambridge, MA-based Constellation Pharmaceuticals (NASDAQ: CNST) is advancing a clinical-stage drug for the indication, too. Forma previously licensed a molecule it discovered, a potential treatment for non-Hodgkin lymphoma, to Celgene (now a subsidiary Bristol Myers Squibb (NYSE: BMY)) and a KRAS inhibitor, meant to treat solid tumors, to Boehringer Ingelheim. The company, which was founded in 2007, is headed by president and CEO Frank Lee, who previously ran global development and commercial strategy for Genentech’s immunology, ophthalmology and infectious diseases divisions.
Classifications
AskAI Classifications
LabelsLinked Companies
